Blueprint MedicinesBPMC
BPMC
About: Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
Employees: 655
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
76% more call options, than puts
Call options by funds: $218M | Put options by funds: $124M
70% more repeat investments, than reductions
Existing positions increased: 139 | Existing positions reduced: 82
28% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 43
4% more funds holding
Funds holding: 302 [Q2] → 314 (+12) [Q3]
4.96% less ownership
Funds ownership: 108.25% [Q2] → 103.29% (-4.96%) [Q3]
18% less capital invested
Capital invested by funds: $7.31B [Q2] → $5.98B (-$1.32B) [Q3]
25% less funds holding in top 10
Funds holding in top 10: 8 [Q2] → 6 (-2) [Q3]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$88
3%
downside
Avg. target
$127
40%
upside
High target
$151
67%
upside
6 analyst ratings
5 positive
83%
1 neutral
17%
0 negative
0%
JMP Securities Reni Benjamin 8% 1-year accuracy 3 / 36 met price target | 38%upside $125 | Market Outperform Reiterated | 9 Dec 2024 |
HC Wainwright & Co. Andrew Fein 31% 1-year accuracy 102 / 328 met price target | 49%upside $135 | Buy Reiterated | 15 Nov 2024 |
Needham Ami Fadia 32% 1-year accuracy 49 / 154 met price target | 49%upside $135 | Buy Reiterated | 15 Nov 2024 |
JP Morgan Brian Cheng 33% 1-year accuracy 6 / 18 met price target | 39%upside $126 | Overweight Initiated | 14 Nov 2024 |
Wells Fargo Derek Archila 44% 1-year accuracy 16 / 36 met price target | 67%upside $151 | Overweight Maintained | 31 Oct 2024 |
Financial journalist opinion
Based on 3 articles about BPMC published over the past 30 days
Neutral
PRNewsWire
6 days ago
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Dec. 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2025 outlook at the 43rd Annual J.P.
Neutral
PRNewsWire
2 weeks ago
Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
-- ASH data reinforce survival benefits of front-line AYVAKIT® (avapritinib) use in patients with advanced SM -- -- Bone density analyses reported in patients with advanced SM underscore disease-modifying effects of AYVAKIT -- CAMBRIDGE, Mass. , Dec. 7, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations that continue to demonstrate the long-term clinical benefits of AYVAKIT® (avapritinib) in advanced systemic mastocytosis (advanced SM), and reflect the company's ongoing partnership with the SM community to redefine the future of patient care – from improving diagnostic rates to raising the bar on treatment outcomes.
Positive
Zacks Investment Research
3 weeks ago
Blueprint Medicines (BPMC) Up 8.7% Since Last Earnings Report: Can It Continue?
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?
Positive
Seeking Alpha
1 month ago
Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs
Blueprint Medicines' core revenue driver, AYVAKIT, has gained traction in systemic mastocytosis and gastrointestinal stromal tumors, reflecting strong market adoption. The recent AYVAKIT expansion into Germany and the potential for further indication of growth underpin Blueprint's valuation and future revenue projections. Blueprint's investigational pipeline, including drugs like BLU-222 and elenestinib, targets various cancers and mast cell disorders, enhancing long-term growth potential.
Positive
Benzinga
1 month ago
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
JP Morgan initiated coverage on Blueprint Medicines Corporation BPMC, a biotech company focused on modulating immune mast cells.
Positive
Zacks Investment Research
1 month ago
BPMC Beats on Q3 Earnings and Sales, Raises '24 View, Stock Up
Blueprint stock gains from better-than-expected third-quarter results, driven by robust Ayvakit sales growth. The company raises revenue guidance for 2024.
Neutral
Seeking Alpha
1 month ago
Blueprint Medicines Corporation (BPMC) Q3 2024 Earnings Call Transcript
Blueprint Medicines Corporation (NASDAQ:BPMC ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Christy Rossi - Chief Operating Officer Mike Landsittel - Chief Financial Officer Fouad Namouni - President-Research & Development Conference Call Participants Marc Frahm - TD Cowen Brad Canino - Stifel Reni Benjamin - Citizens JMP Paul Jeng - Guggenheim Tommie Reerink - Goldman Sachs Derek Archila - Wells Fargo Mike Ulz - Morgan Stanley Ami Fadia - Needham Markus Schweiger - Oppenheimer Peter Lawson - Barclays Laura Prendergast - Raymond James David Lebowitz - Citi Sudan Loganathan - Stephens Operator Good morning. My name is Nadia, and I'll be your conference operator today.
Negative
Zacks Investment Research
1 month ago
Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates
Blueprint Medicines (BPMC) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $2.20 per share a year ago.
Neutral
PRNewsWire
1 month ago
Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
-- Achieved $128.2 million in AYVAKIT net product revenues in the third quarter 2024 -- -- Raising AYVAKIT net product revenue guidance to $475 million to $480 million for 2024 -- -- On track to initiate the registration-enabling HARBOR Part 2 study of elenestinib in ISM by year end -- CAMBRIDGE, Mass. , Oct. 30, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the third quarter ended Sept 30, 2024, and provided updated financial guidance.
Positive
Zacks Investment Research
2 months ago
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.
Charts implemented using Lightweight Charts™